Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin
- PMID: 40163284
- DOI: 10.1007/s10096-025-05117-5
Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin
Abstract
Invasive fungal infections, particularly those caused by Candida species, represent an increasing cause of hospital-related morbidity and mortality. Most commonly Candida spp. is the causative agent of candidemia and invasive candidiasis. In this report we present a complex case of Candida albicans spondylodiscitis, successfully treated with rezafungin, a new echinocandin suitable for weekly outpatient administration. This case illustrates the first documented use of rezafungin in an outpatient setting for C. albicans spondylodiscitis, demonstrating its potential in managing complex fungal infections.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The patient’s written consent was obtained. The authors affirm that human research participants provided informed consent for publication of the images in Fig. 2. Competing interests: The authors declare no competing interests.
References
-
- Adelhoefer SJ, Gonzales MR, Bedi A, Kienzle A, Backer HC, Androvic O et al (2024) Candida spondylodiscitis: a systematic review and meta-analysis of seventy-two studies. Int Orthop 48:5–20. https://doi.org/10.1007/s00264-023-05989-2 - DOI - PubMed
-
- Cornely OA, Sprute R, Bassetti M, Chen SCA, Groll AH, Kurzai O et al (2025) Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in Cooperation with ISHAM and ASM. Lancet Inf Dis S. https://doi.org/10.1016/S1473-3099(24)00749-7 Online ahead of print 1473-3099(24)00749-7 - DOI
-
- Thompson GR, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M et al (2024) Efficacy and safety of Rezafungin and Caspofungin in candidemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. Lancet Inf Dis 24:319–328. https://doi.org/10.1016/S1473-3099(23)00551-0 - DOI
-
- Zhao Y, Prideaux B, Baistrocchi S, Shepard DC, Perlin DS (2019) Beyond tissue concentrations: antifungal penetration at the site of infection. Med Mycol 57:S161–S167. https://doi.org/10.1093/mmy/myy067 - DOI - PubMed - PMC
-
- Viceconte G, Buonomo AR, Esposito N, Cattaneo L, Somma T, Scirocco MM et al (2024) Salvage therapy with Rezafungin for Candida parapsilosis spondylodiscitis: a case report from expanded access program. Microorganisms 12:903. https://doi.org/10.3390/microorganisms12050903 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
